Board of Directors


    David J. Earp, JD, PhD

    President & CEO
  • David J. Earp, J.D., Ph.D. - President & CEO

    David J. Earp, J.D., Ph.D., has served as the President & CEO of Circle since October 2013. Previously, David held various roles at Geron Corporation (GERN), including chief patent counsel, chief legal officer and senior vice president of corporate transactions, building a broad IP portfolio and playing an integral role in numerous partnering, licensing and collaboration deals. He led the spin-out of Geron’s nuclear transfer technology into StART Licensing, Inc., and its subsequent acquisition by Viagen Corp. (Austin, Texas). He served on the boards of StART and Viagen, including as executive chairman of Viagen and led the sale of the company to TransOva Genetics (subsequently acquired by Intrexon). David was also a member of the board of directors of TA Therapeutics Ltd. (Hong Kong, PRC). He was previously a partner in the intellectual property law firm of Klarquist Sparkman, LLP (Portland, Oregon). He currently also serves as a board member of Sienna Cancer Diagnostics (Melbourne, Australia).
    David received his B.Sc. (with first class honours) in microbiology from the University of Leeds, his Ph.D. in biochemistry and molecular biology from the University of Cambridge, and his J.D. (magna cum laude) from the Northwestern School of Law of Lewis and Clark College. He was a postdoctoral research fellow at the University of California, Berkeley / USDA PGEC.

    Douglas Crawford, PhD

    Board Member
  • Douglas Crawford, Ph.D. - Board Member

    Douglas Crawford, Ph.D., is a founder and managing director of Mission Bay Capital, a seed-stage venture fund that makes pivotal early-stage investments in bioscience companies. Mission Bay Capital has helped 25 entrepreneurial teams launch cool companies. He is also the associate director of QB3, the California Institute for Quantitative Biosciences. He is a board member of Circle Pharma, Delpor, Magnamosis, Magnap, Ocular Dynamics, and SiteOne Therapeutics. Doug received his Ph.D. in biochemistry from UCSF.

    Walter H. Moos, PhD

    Board Member
  • Walter H. Moos, PhD - Board Member

    Walter H. Moos, Ph.D., retired as President of SRI Biosciences in early 2016 after more than a decade at the independent nonprofit SRI International (Stanford Research Institute). Prior to SRI he served as Chairman and CEO of MitoKor (Migenix), and as a Vice President at Chiron (Novartis) and Warner-Lambert / Parke-Davis (Pfizer). His teams have advanced numerous pharmaceutical products from discovery to commercialization. He has served on about 20 business and scientific boards, including Amunix, Oncologic (Aduro), Onyx (Amgen), Rigel and the Biotechnology Industry Organization (BIO). Walter holds Ph.D. and A.B. degrees in chemistry from UC Berkeley and Harvard, respectively.

    Matthew P. Jacobson, PhD

    Co-Founder and SAB Member
  • Matthew P. Jacobson, Ph.D. - Co-Founder and SAB Member

    Matt Jacobson, Ph.D., has been a faculty member in the Department of Pharmaceutical Chemistry at UCSF since 2002, and was appointed the Chair of the Department effective January 2016. He earned his Ph.D. in physical chemistry at MIT, and completed post-doctoral research at Oxford and Columbia. Matt’s research focuses on computational biophysics and computer-aided drug design; he is the author of over 120 publications. Software written by Matt and his collaborators is widely used in the pharmaceutical industry; he serves on the Scientific Advisory Board of Schrödinger, LLC, and is a co-founder of Global Blood Therapeutics (NASDAQ: GBT). Matt received the NSF CAREER award, an Alfred P. Sloan Fellowship, and a School of Pharmacy teaching award. He has served on the editorial boards of several journals, including Biochemistry and PLoS Computational Biology.

    R. Scott Lokey, PhD

    Co-Founder and SAB Chairman
  • R. Scott Lokey, Ph.D. - Co-Founder and SAB Chairman

    R. Scott Lokey, Ph.D., has been a faculty member in the department of Chemistry and Biochemistry at the University of California Santa Cruz since 2002. He received a B.S. in chemistry from Trinity University in San Antonio, Texas, and a Ph.D. in bioorganic chemistry from University of Texas, Austin in bioorganic chemistry. Scott held a NIH postdoctoral fellowship at the Harvard Institute of Chemistry and Cell Biology, where he worked on the identification of cyclic peptide modulators of actin dynamics. His current research interests include the basic science underlying cell permeability of cyclic peptides, and the development of methodologies for synthesizing libraries of cyclic peptides for the discovery of bioactive ligands against intracellular targets. Scott and Matt Jacobson have collaborated for more than a decade on the application of computational approaches for predicting membrane permeability in "beyond Rule-of-5" molecules, with a particular focus on macrocyclic peptides.

    Gregory Naeve, PhD

    Board Observer
  • Gregory Naeve, Ph.D. - Board Observer

    Gregory Naeve, Ph.D., is currently the Rinat Lead and Head of Pfizer’s San Francisco office for Strategic Research Partnerships in the External Research, Development, & Innovation unit. In this role, Greg is responsible for liaising with Pfizer Scientists to identify and institute strategic partnerships that address internal technology and pipeline needs. Prior to Pfizer he worked as a venture capitalist with the San Francisco-based life science venture fund, The Column Group, a firm focused on creating biotechnology companies to develop novel therapeutics and technologies. Prior to that he was the President and Chief Scientific Officer of Parallax Biosystems, a company he co-founded to develop a molecular detection platform with applications in pre-clinical drug discovery and diagnostics. Before Parallax he held positions at Neurocrine Biosciences and Amgen working to develop new therapies for neurodegenerative disorders. He received his Ph.D. in biochemistry from the University of Southern California.